Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations

Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy

(2021) Shota Yamamoto et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Encapsulation and pH-responsive release of bortezomib by dopamine grafted hyaluronate nanogels

(2021) Lei Liu et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration

(2020) Kai Kaarniranta et al.   PROGRESS IN RETINAL AND EYE RESEARCH

Preparation, characterization and in vitro–in vivo evaluation of bortezomib supermolecular aggregation nanovehicles

(2020) Ming-yue Chen et al.   JOURNAL OF NANOBIOTECHNOLOGY

Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells

(2020) Daniele Tibullo et al.   Biomolecules

Bortezomib-Encapsulated CuS/Carbon Dots Nanocomposites for Enhanced Photothermal Therapy via Stabilization of Polyubiquitinated Substrates in the Proteasomal Degradation Pathway

(2020) Ying Yu et al.   ACS Nano

Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia

(2020) Vijay Sagar Madamsetty et al.   LEUKEMIA & LYMPHOMA

Spatiotemporally Targeted Nanomedicine Overcomes Hypoxia-Induced Drug Resistance of Tumor Cells after Disrupting Neovasculature

(2020) Jinjin Chen et al.   NANO LETTERS

ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF‐κB in multiple myeloma

(2020) Jifeng Jiang et al.   Cancer Medicine

Inhibition of Multiple Myeloma Using 5-Aza-2ʹ-Deoxycytidine and Bortezomib-Loaded Self-Assembling Nanoparticles

(2020) Feifei Che et al.   Cancer Management and Research

Programming cell pyroptosis with biomimetic nanoparticles for solid tumor immunotherapy

(2020) Pengfei Zhao et al.   BIOMATERIALS

The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA

(2020) Alina Muenchow et al.   Cell Death & Disease

The active second-generation proteasome inhibitor oprozomib reverts the oxaliplatin-induced neuropathy symptoms

(2020) Francesca Felicia Caputi et al.   BIOCHEMICAL PHARMACOLOGY

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

(2020) Shaji K Kumar et al.   LANCET ONCOLOGY

Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells

(2020) Wei Wei et al.   MEDICAL ONCOLOGY

Engineering precision nanoparticles for drug delivery

(2020) Michael J. Mitchell et al.   NATURE REVIEWS DRUG DISCOVERY

Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma

(2020) Cinzia Federico et al.   Nature Communications

Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab

(2019) Dawei Wang et al.   ONCOGENE

Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization

(2019) Ning Wang et al.   JOURNAL OF CONTROLLED RELEASE

Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model

(2019) Chulwon Kim et al.   Biomolecules

Alginate Gel Reinforcement with Chitin Nanowhiskers Modulates Rheological Properties and Drug Release Profile

(2019) Valentina A. Petrova et al.   Biomolecules

The NEDD4‐1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma

(2019) Xi Huang et al.   INTERNATIONAL JOURNAL OF CANCER

Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-κB activity in hepatocellular carcinoma

(2019) Xiaolan Zhang et al.   Cell Death & Disease

Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment

(2019) Roser Velasco et al.   JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM

Cellular quality control by the ubiquitin-proteasome system and autophagy

(2019) Christian Pohl et al.   SCIENCE

Histone H2A-peptide-hybrided upconversion mesoporous silica nanoparticles for bortezomib/p53 delivery and apoptosis induction

(2019) Jiamin Rong et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance

(2019) Silpa Narayanan et al.   DRUG RESISTANCE UPDATES

Attenuation of STAT3 Signaling Cascade by Daidzin Can Enhance the Apoptotic Potential of Bortezomib against Multiple Myeloma

(2019) Min Hee Yang et al.   Biomolecules

Injectable Coacervate Hydrogel for Delivery of Anticancer Drug-Loaded Nanoparticles in vivo

(2018) Ashlynn L. Z. Lee et al.   ACS Applied Materials & Interfaces

Dual pH-Responsive Shell-Cleavable Polycarbonate Micellar Nanoparticles for in Vivo Anticancer Drug Delivery

(2018) Shaoqiong Liu et al.   ACS Applied Materials & Interfaces

Recent progress in dendrimer-based nanomedicine development

(2018) Yejin Kim et al.   ARCHIVES OF PHARMACAL RESEARCH

Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib

(2018) Carlyn Rose C. Tan et al.   CLINICAL PHARMACOKINETICS

Bortezomib-loaded solid lipid nanoparticles: preparation, characterization, and intestinal permeability investigation

(2018) Mohammad Mahmoudian et al.   DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Ubiquitination: Friend and foe in cancer

(2018) Mohammed A. Mansour   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Dendrimers for Drug Delivery

(2018) Abhay Chauhan   MOLECULES

Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma

(2018) Zhaoxin Gu et al.   Acta Biomaterialia

Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer

(2018) Yijing Liu et al.   CHEMICAL SOCIETY REVIEWS

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

(2018) Neeraj Gupta et al.   CLINICAL PHARMACOKINETICS

A Targeted and pH-Responsive Bortezomib Nanomedicine in the Treatment of Metastatic Bone Tumors

(2018) Mingming Wang et al.   ACS Applied Materials & Interfaces

Trehalose activates autophagy and decreases proteasome inhibitor-induced endoplasmic reticulum stress and oxidative stress-mediated cytotoxicity in hepatocytes

(2017) Yuichi Honma et al.   HEPATOLOGY RESEARCH

Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma

(2017) Dan T. Vogl et al.   LEUKEMIA & LYMPHOMA

Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy

(2017) Marisa Granato et al.   Scientific Reports

Growth Factor-Loaded Nano-niosomal Gel Formulation and Characterization

(2016) Saeid Moghassemi et al.   AAPS PHARMSCITECH

Cancer Cell Membrane–Biomimetic Nanoparticles for Homologous-Targeting Dual-Modal Imaging and Photothermal Therapy

(2016) Ze Chen et al.   ACS Nano

Commentary on "Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents"

(2016) K. D. Tew   CANCER RESEARCH

Ixazomib: First Global Approval

(2016) Matt Shirley   DRUGS

Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone

(2016) Elisabet E. Manasanch et al.   LEUKEMIA & LYMPHOMA

Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date

(2016) Daniel Bobo et al.   PHARMACEUTICAL RESEARCH

Small molecule therapeutics targeting F-box proteins in cancer

(2016) Yuan Liu et al.   SEMINARS IN CANCER BIOLOGY

pH/NIR Light-Controlled Multidrug Release via a Mussel-Inspired Nanocomposite Hydrogel for Chemo-Photothermal Cancer Therapy

(2016) Amin GhavamiNejad et al.   Scientific Reports

A Review of Clinical Translation of Inorganic Nanoparticles

(2015) Aaron C. Anselmo et al.   AAPS Journal

Protease-Mediated Release of Chemotherapeutics from Mesoporous Silica Nanoparticles to ex Vivo Human and Mouse Lung Tumors

(2015) Sabine H. van Rijt et al.   ACS Nano

Synthesis and Applications of Boronic Acid-Containing Polymers: From Materials to Medicine

(2015) William L. A. Brooks et al.   CHEMICAL REVIEWS

Catechol-grafted dendrimer with a neutral shell allows pH-triggered “off–on” release of bortezomib

(2015) Mingming Wang et al.   JOURNAL OF CONTROLLED RELEASE

Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma

(2015) Guendalina Zuccari et al.   JOURNAL OF CONTROLLED RELEASE

Smart micelle@polydopamine core–shell nanoparticles for highly effective chemo–photothermal combination therapy

(2015) Ruirui Zhang et al.   Nanoscale

A smart magnetic nanoplatform for synergistic anticancer therapy: manoeuvring mussel-inspired functional magnetic nanoparticles for pH responsive anticancer drug delivery and hyperthermia

(2015) Arathyram Ramachandra Kurup Sasikala et al.   Nanoscale

Tumor extracellular acidity activated “off–on” release of bortezomib from a biocompatible dendrimer

(2015) Mingming Wang et al.   Biomaterials Science

Chitosan magnetic nanoparticles for pH responsive Bortezomib release in cancer therapy

(2014) Gozde Unsoy et al.   BIOMEDICINE & PHARMACOTHERAPY

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

(2014) J. E. Chang et al.   BLOOD

The ubiquitin–proteasome system: opportunities for therapeutic intervention in solid tumors

(2014) Daniel E Johnson   ENDOCRINE-RELATED CANCER

Melatonin as a proteasome inhibitor. Is there any clinical evidence?

(2014) Jerry Vriend et al.   LIFE SCIENCES

Development of P22 Viral Capsid Nanocomposites as Anti-Cancer Drug, Bortezomib (BTZ), Delivery Nanoplatforms

(2014) Junseon Min et al.   MACROMOLECULAR BIOSCIENCE

Proteasome inhibitor inhibits proliferation and induces apoptosis in renal interstitial fibroblasts

(2014) Bingbing Zhu et al.   Pharmacological Reports

Chemotherapy-induced peripheral neurotoxicity: A critical analysis

(2013) Susanna B. Park et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Reduction-sensitive degradable micellar nanoparticles as smart and intuitive delivery systems for cancer chemotherapy

(2013) Huanli Sun et al.   Expert Opinion on Drug Delivery

The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma

(2013) Elisabet E. Manasanch et al.   LEUKEMIA & LYMPHOMA

Ubiquitin-Proteasome Pathway and Prostate Cancer

(2013) Fang-Zhi Chen et al.   ONKOLOGIE

Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib

(2013) Julia S. Gelman et al.   PLoS One

JNK and Macroautophagy Activation by Bortezomib Has a Pro-Survival Effect in Primary Effusion Lymphoma Cells

(2013) Marisa Granato et al.   PLoS One

The Significance of Ubiquitin Proteasome Pathway in Cancer Development

(2013) Azmi Yerlikaya et al.   Recent Patents on Anti-Cancer Drug Discovery

Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation

(2013) F Rapino et al.   Cell Death & Disease

Well-Defined, Reversible Boronate Crosslinked Nanocarriers for Targeted Drug Delivery in Response to Acidic pH Values andcis-Diols

(2012) Yuanpei Li et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

MG132, a proteasome inhibitor, induces apoptosis in tumor cells

(2012) Na GUO et al.   Asia-Pacific Journal of Clinical Oncology

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

(2012) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

(2012) Philippe Moreau et al.   CLINICAL PHARMACOKINETICS

Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial

(2012) Seok Jin Kim et al.   EUROPEAN JOURNAL OF CANCER

Targeting the Ubiquitin+Proteasome System in Solid Tumors

(2012) James J. Driscoll et al.   SEMINARS IN HEMATOLOGY

VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study

(2011) Julie E. Chang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study

(2011) Ticiana B. Leal et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation

(2011) Changyou Li et al.   CANCER LETTERS

Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29

(2011) Bettina Ebert et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma

(2011) M. A. Weniger et al.   CLINICAL CANCER RESEARCH

Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs

(2011) Tak Chan   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells

(2011) N E Franke et al.   LEUKEMIA

Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma

(2011) T. Hideshima et al.   MOLECULAR CANCER THERAPEUTICS

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

(2010) Irene M. Ghobrial et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model

(2010) Ajita V. Singh et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

(2010) Donna E. Reece et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer

(2010) William J. Irvin et al.   Clinical Breast Cancer

Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry

(2010) E. Genin et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

(2010) Jia Ruan et al.   JOURNAL OF CLINICAL ONCOLOGY

Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: anin vitroevaluation

(2010) Wei Wei et al.   Nanomedicine

Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets

(2010) Lynn Bedford et al.   NATURE REVIEWS DRUG DISCOVERY

Stability of unused reconstituted bortezomib in original manufacturer vials

(2010) Joshua P Vanderloo et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

The 20S Proteasome as an Assembly Platform for the 19S Regulatory Complex

(2009) Klavs B. Hendil et al.   JOURNAL OF MOLECULAR BIOLOGY

Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells

(2009) Hongjuan Dong et al.   LEUKEMIA & LYMPHOMA

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer

(2009) Giorgio V. Scagliotti et al.   LUNG CANCER

Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models

(2009) T. M. Pitts et al.   MOLECULAR CANCER THERAPEUTICS

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Bortezomib-Resistant Nuclear Factor- B Activity in Multiple Myeloma Cells

(2008) S. Markovina et al.   MOLECULAR CANCER RESEARCH

Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro

(2007) Ferit Avcu et al.   THROMBOSIS RESEARCH